GlassScriptPhysician profile
Sajeev Anand
NPI 1194816017
$11,628.13
in general payments reported to CMS, 2019-2025
63 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,722 · 2020: $1,871 · 2021: $3,451 · 2022: $2,826 · 2023: $188 · 2024: $176 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,095.64 | 2019-2025 | Talvey, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $1,013.50 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $680.69 | 2019-2022 | |
| Pfizer INC. | $662.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $610.62 | 2019-2024 | Opdivo |
| Amgen INC. | $579.22 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $492.64 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $485.76 | 2019-2022 | |
| Genzyme Corporation | $430.04 | 2019-2025 | |
| Celgene Corporation | $407.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $357.64 | 2019-2022 | |
| Incyte Corporation | $337.74 | 2019-2025 | Zynyz, Monjuvi |
| Lilly USA, LLC | $330.30 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $326.13 | 2019-2025 | Keytruda |
| Rigel Pharmaceuticals, INC. | $298.88 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajeev Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.